MedTrace Logo

Blind Elderly Melatonin Treatment Study

NCT00692094 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2019-11-27

Study results available
· View outcomes & findings →

Summary

The primary focus of this five-year study will be to optimize the melatonin dosing regimen for synchronizing the body clocks of elderly blind individuals to the 24-hour day.

Conditions

Interventions

BIOLOGICAL

Melatonin

0.025 mg-0.5 mg, daily given at a time when it is expected to delay the timing of the body clock.

BIOLOGICAL

Melatonin

0.025 mg - 0.5 mg, daily, at a time when melatonin should advance the timing of their body clock.

BIOLOGICAL

Melatonin

0.025 mg - 10 mg, daily, at a time when melatonin should advance the timing of their body clock.

BIOLOGICAL

Melatonin

0.025 mg - 20 mg, daily, at a time when the melatonin should advance the timing of the body clock.

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Oregon Health and Science University

    lead OTHER

Principal Investigators

  • Alfred J Lewy, MD, PhD · Oregon Health and Science University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2008-05-31
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00692094 on ClinicalTrials.gov